Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955080 | 1.00 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL15010827 | 0.83 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL29508599 | 0.83 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL1396618 | 0.83 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL7978271 | 0.81 | ALDH1A1 (0.61) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL7241535 | 0.81 | ALDH1A1 (0.61) | MEN1KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL4841354 | 0.79 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL319539 | 0.79 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL29427029 | 0.79 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 | |
| SCHEMBL29525163 | 0.79 | MGLL (0.48) | MGLLMEN1KMT2ATRPV6ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2024-02-08 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | MERCK SHARP & DOHME LLC (US) | 2023-07-11 | — | — | US | disclosed |
| EP-4051678-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021086833-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021086833-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | MERCK SHARP & DOHME LLC | 2021-04-29 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| CN-101048369-A | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| CN-101035774-A | Modulators of CRTH-2 receptor activity for the treatment of prostaglandin D2 mediated diseases | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | CN | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| EP-1611091-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297208-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | MGLL 2399/4885MEN1 528/4885KMT2A 382/4885 |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | MGLL 3158/4885MEN1 4141/4885KMT2A 3314/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | MGLL 1685/4885MEN1 3390/4885KMT2A 1676/4885 |
| US-20240083913-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | MGLL 2399/4885MEN1 528/4885KMT2A 382/4885 |
| US-12291538-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | MGLL 2399/4885MEN1 528/4885KMT2A 382/4885 |
| US-11697657-B2 | Small molecule inhibitors of KRAS G12C mutant | KRAS, NRAS, HRAS | MGLL 2464/4885MEN1 529/4885KMT2A 381/4885 |
| US-20240043448-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | MGLL 2399/4885MEN1 528/4885KMT2A 382/4885 |
| US-20210122764-A1 | Small Molecule Inhibitors of KRAS G12C Mutant | KRAS, NRAS, HRAS | MGLL 2464/4885MEN1 529/4885KMT2A 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.